ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Advisors Approve New Grant Programs Worth $100 Million

March 27, 2009

FDA, NCI Seek Compromise On Survival Endpoints

June 16, 1989

In Brief: OMB tells NCI Mislead Congress, Refuses Higher Budget; Ford Says He Support Program

March 28, 1975

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

February 25, 2011

AIDS Vaccine Intervention Progress Reported

July 5, 1985

Has The Pendulum Swing too Far Toward Grants? NCI, NCAB Ponder Best Way to Stimulate Work In New areas

December 5, 1980